Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.
AffiliationDepartment of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester
MetadataShow full item record
AbstractDespite better understanding of it's molecular biology, non-small cell lung cancer (NSCLC) remains a challenging disease to treat. Unfortunately, treatment options are still very limited and prognosis for advanced disease is poor. Immune surveillance plays a crucial role in a host's defence against tumour cells, and this is particular relevant for lung cancer due to it's high somatic mutational load, which increases the chances for the immune system to recognize cancer cells as 'non-self'. Novel immunotherapies are emerging as an effective treatment for this disease. In this review, we present the data on immune checkpoint inhibitors for NSCLC, describing their mechanism of action, data efficacy from recent clinical trials, and strategies to select patients more likely to benefit from these agents.
CitationImmune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. 2016, 18 (9):59 Curr Oncol Rep
JournalCurrent Oncology Reports